Last reviewed · How we verify
Foralumab TZLS-401 100 µg
At a glance
| Generic name | Foralumab TZLS-401 100 µg |
|---|---|
| Sponsor | Tiziana Life Sciences LTD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease (PHASE2)
- Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foralumab TZLS-401 100 µg CI brief — competitive landscape report
- Foralumab TZLS-401 100 µg updates RSS · CI watch RSS
- Tiziana Life Sciences LTD portfolio CI